IMMUNITY.
RECRUITED.

UNMASKING CANCER CELL CAMOUFLAGE

COMPANY PRESENTATION | August 2022



Disclaimer

This presentation has been made available to you with the consent of KAHR Medical Ltd. (the "Company"). This presentation may not be reproduced or redistributed in whole or in part, nor may its contents be disclosed to any other person or entity.

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any officer, director, employee, agent or advisor of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire in connection with your investigation of the Company. Information provided in this presentation and the accompanying oral presentation speak only as of the date hereof.

This presentation is made pursuant to either Rule 163B of the Securities Act of 1933, as amended (the "Securities Act"), or Section 5(d) of the Securities Act, and is intended solely for investors that are qualified institutional buyers or institutional accredited investors solely for the purposes of familiarizing such investors with the Company and determining whether such investors might have an interest in a securities offering contemplated by the Company. Any such offering of securities will only be made by means of a registration statement (including a prospectus) filed with the Securities and Exchange Commission, after such registration statement becomes effective. No such registration statement has been filed, or become effective, as of the date of this presentation. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This presentation contains forward-looking statements about the Company and its industry that involve substantial risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations and assumptions regarding the future of its business, its future plans and strategies and other future conditions. These statements involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "would," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to numerous risks, uncertainties and other important factors, some of which cannot be predicted or quantified, that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result, you should not rely on these statements as predictions of future events. The events and circumstances reflected in any forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. In addition, statements such as "we believe" and similar statements reflect the Company's beliefs and opinions on the relevant subject. These statements are based upon information available to the Company as of the date of this presentation and are made only as of the date hereof. While the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and the Company's statements should not be read to indicate that it has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Moreover, new risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties that may cause the Company's actual results to differ materially from those projected in the Company's forward-looking statements. Except as required by applicable law, the Company does not intend to update or revise any forward-looking statements contained in this presentation, whether as a result of any new information, future events or otherwise, or to reflect the occurrence of unanticipated events. You should read this presentation with the understanding that the Company's actual future results of operations, performance and achievements may be materially different from what the Company expects. The Company qualifies all forward-looking statements in this presentation or made orally during this presentation by reference to these cautionary statements.

This presentation contains statistical data, estimates, forecasts and information concerning the Company's industry, including market size and growth of the market in which the Company participates, that are based on independent industry publications and reports as well as the Company's internal sources and general knowledge of, and expectations concerning, the industry. The industry market and sales positions, shares, market sizes and growth estimates included in this presentation are based on estimates using the foregoing independent industry publications and the Company's internal data and estimates based on data from various industry analyses, the Company's internal research and adjustments and assumptions that the Company believes to be reasonable. Although the Company has no reason to believe that this industry information is not reliable, it has not independently verified data from industry publications and analyses and cannot guarantee their accuracy or completeness. In addition, the Company believes that the data regarding the industry and industry market and sales positions, shares, market sizes and growth provide general guidance but are inherently imprecise.

This presentation discusses product candidates that are investigational only and have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The Company's design logo and other registered or common law trademarks, service marks or trade names appearing in this presentation are the property of the Company. This presentation also contains trademarks, trade names and service marks of other companies that are the property of their respective owners. The Company does not intend its use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of the Company by, these other companies. Solely for convenience, the Company's trademarks and tradenames referred to in this presentation may appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable law, its rights or the right of the applicable licensor, to these trademarks and tradenames.

Company Highlights

Differentiated Pipeline

- Novel, next generation potential across **three programs in solid and hematological malignancies**
- Lead candidate DSP107 designed to target **CD47/SIRPα and 41BB specifically and conditionally** in the tumor microenvironment
- Versatile MIRP platform **targeting innate and adaptive immunity**

Multiple Near-Term Catalysts

- **Anticipated data readouts** for DSP107 in Q2 2023 in NSCLC (phase II) and in Q4 2022 in heme malignancies (phase I)
  - Dose escalation portion of Phase I/II data **demonstrates favorable preliminary safety profile and monotherapy activity** in solid tumors
- Expected IND filing for DSP502 and DSP216 in 2024

Cash Runway

- Raised **~$110 million** to date
- Investors include **aMoon, BVF, DAFNA, Cancer Focus Fund**

Experienced Leadership

- **Experienced leadership** and executive team with track record of success
- Supported by leading scientific advisory board

Experienced Leadership Team

Aron Knickerbocker, MBA

Board Chairman

aulos

Genentech

FivePrime

Bristol Myers Squibb

AMGEN

Yaron Pereg, PhD

Chief Executive Officer

Genentech

BIOLINERX

CELLECT

Tomer Cohen, MBA

Chief Financial Officer

LOCUST WALK

BARCLAYS

Goldman Sachs

Adam Foley-Comer, MD

Chief Medical Officer

Roche

BIOLINERX

QUINTILES

IMMUNE Pharmaceuticals

Ayelet Chajut, PhD

Chief Technology Officer

Pluristem

ROSETTA GENOMICS

Quark Pharmaceuticals

compugen

IMMUNITY. RECRUITED.

Effectively treating cancer requires a multifaceted approach



Selectively disabling cancer defense mechanism

WHILE

Recruiting a local targeted immune attack

IMMUNITY. RECRUITED.

Versatile Multifunctional Immunotherapeutic Platform for Solid and Hematological Malignancies

MULTIFUNCTIONAL IMMUNE RECRUITMENT PROTEIN (MIRP)

Enabled us to design dual-targeting fusion proteins capable of:

1. Inhibiting key evasion markers on cancer cells
2. Activating innate and adaptive anti-tumor immunity



IMMUNITY. RECRUITED.

MIRP Platform - Customized, Modular and Flexible Design



Enhanced, Tumor-Localized Immune Cell Recruitment & Activation With Potential to Improve Safety and Efficacy

DSP (Dual Signaling Protein)

Combined checkpoint inhibition and immune co-stimulation

DSP107

4-1BB activator – *CD47-conditional T-cell activation*

CD47 inhibitor – *Trimeric binding for cancer specific blocking*



DSP-Fc (Dual Signaling Protein With Fc Domain)

Dual checkpoint inhibition for tumoricidal response

DSP502

PVR inhibitor – *Dual PD1/TIGIT inhibition with DNAMI potentiation potential*

PD-L1 inhibitor – *T and NK cell activation*

Active IgG1 Fc – *Half-life extension potential, ADCC activity*



DSP216

CD47 inhibitor – *Avidity driven for cancer specific blocking*

HLA-G inhibitor – *Inhibition of LILRB1,LILRB2*

Inactive Fc – *Half-life extension potential*



Wholly Owned, Focused and Differentiated Pipeline

Program	Targets	Indications	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Anticipated Milestones
DSP107	CD47 4-1BB	Advanced Solid Tumors, NSCLC			DSP107 ± atezolizumab*			Phase II interim data Q2/23
		AML / MDS			DSP107 ± azacitidine + venetoclax			Phase Ib interim data Q4/22
DSP502	PVR PD-L1	Oncology						IND submission H1 2024
DSP216	HLA-G CD47	Oncology						IND submission H2 2024

*Clinical trial collaboration and supply agreement with Roche for the PD-L1 inhibitor atezolizumab (TECENTRIQ®)

IMMUNITY. RECRUITED.

Key Anticipated Milestones

Program MOA	Indication	2022		2023		2024	
		1H	2H	1H	2H	1H	2H
DSP107 CD47 inhibitor 4-1BB activator	**Solid Tumors, NSCLC**	Ph I Topline Results		Ph I/II NSCLC Interim Results	Ph I/II NSCLC Topline Results		
	AML/MDS		Ph Ib AML Interim Results		Ph Ib AML Topline Results		
DSP502 PVR inhibitor PD-L1 inhibitor Active IgG1 Fc	**Oncology**		IND-enabling activities		File IND		
DSP216 CD47 inhibitor HLA-G inhibitor Inactive Fc	**Oncology**		IND-enabling activities			File IND	

DSP107

MIRP Type	**DSP**
Targets	**CD47, 4-1BB**
Primary Cell Target	**mϕ macrophages, T cells**
Mechanism of Action	**Unleash mϕ via ‘Don’t Eat Me’ blockade, Activate 4-1BB+ T cells**

DSP107 – Differentiated CD47 Targeting Compound

First-generation CD47 blocking agents are mainly active in hematological malignancies and limited by anemia

Dual MOA
designed to activate innate and adaptive immunity

Favorable safety
without hematological toxicities observed

Strongly positioned
for treatment of solid and hematological malignancies

Phase I data demonstrates unique and differentiated features



Post DSP107 treatment biopsy data



Triggering T and NK-cell infiltration into tumor microenvironment



No binding to red blood cells observed



Increasing tumor necrosis (red) and immune cell infiltration (blue)

Trimeric Structure Design For Tumor Selectivity and Improved Safety

Trimeric ligand ends designed to enable:

1. Cancer selective binding to overexpressed CD47 on tumor cells, minimizing RBC binding and associated toxicities

2. Conditional 4-1BB mediated T cell activation dependent on trimeric binding to CD47 on cancer cells

Trimeric 4-1BBL



3 SIRPα for
CD47 Checkpoint Targeting

Cytolytic T cell activation

T cell Proliferation

Checkpoint inhibition

Tumor microenvironment modulation

IMMUNITY. RECRUITED.

DSP107 Structure Designed to Safely Unlock 4-1BB Potential

Phase I/II Data Demonstrated Absence of 4-1BB Related Hepatotoxicity



Modified from: Bremer E.; ISRN Oncology; Volume 2013, Article ID 371854

Designed for Synergistic Innate & Adaptive Immune Activation

CD47 overexpressed on cancer cells, delivers **“don’t eat me”** signal inhibiting macrophage activity (phagocytosis)



4-1BB mediated **T-cell** binding stimulates their **activation**

CD47 binding blocks “don’t eat me” signal, **enabling macrophage activity**

Macrophages ingest cancer cells with blocked “don’t eat me” signal and **present cancer antigens**, amplifying the immune response

DSP107 Potential as a Monotherapy and in Combination Therapies

DSP107 monotherapy

Triggers macrophage mediated phagocytosis and T cell cytotoxicity



DSP107 combination with therapeutic Antibodies IgG1 mAbs

(cetuximab, trastuzumab…)

Enhances antibody-dependent cellular phagocytosis (ADCP)



DSP107 combination with PD1/PD-L1 Checkpoint Inhibitors

(atezolizumab, pembrolizumab…)

Enhances T cell activation



DSP107 combination with pro-apoptotic agents

(chemotherapy, hypomethylating agents and BCL2 inhibitors)

Increases “eat me” signals



Preclinical Studies Support Differentiated Potential Dual MoA

Dual MOA
designed to activate innate and adaptive immunity

Favorable safety
without hematological or hepato-toxicities in NHP observed

Monotherapy potential
for treatment of solid and hematological malignancies

Comprehensive preclinical package demonstrated differentiated features

Carcinoma and Lymphoma cell lines



Triggering cancer cell death by phagocytosis as a single agent





Inducing 4-1BB activation, T-cell proliferation and killing potential against cancer cells

Lymphoma and Ovarian Carcinoma models



Demonstrating single agent anti tumor activity in mice models

DSP107 Clinical Program

Advanced Solid Tumors

Phase 1 – Dose escalation (n ~ 30)

Accelerated dose escalation; Then 3+3

- DSP107 ✓
- DSP107 + atezolizumab

RP2D

Phase 2 – Expansion Cohort (n = 70)

- DSP107
- DSP107 + atezolizumab

Potential regulatory path

2L NSCLC patients who progressed on PD1/PD-L1 therapies

Enrolling sites: Pittsburgh, Colorado, Kansas, Thomas Jefferson; Sites under evaluation: San-Diego, Augusta, Chapel Hill, University of Texas

Hematological Malignancies

Phase I Dose escalation (n ~ 36)

Dose escalation N=6-8/cohort

- DSP107 ± azacytidine
- DSP107 + azacytidine + venetoclax

High risk R/R MDS/CMML and AML who failed up to 2 prior therapeutic regimes

RP2D

Phase 2 – Expansion
Details to be announced following EOPI meeting with the FDA

Lead site: MD Anderson Cancer Center

RP2D: Recommended Phase 2 dose; NSCLC: Non-small cell lung cancer; MDS: Myelodysplastic syndromes; AML: Acute myeloid leukemia

IMMUNITY. RECRUITED.

Trial Design and Key Inclusion Criteria

Part 1 – Monotherapy and Combination Dose Escalation in Advanced Solid Tumor Patients





Trial Design:

- Patients with advanced solid tumors (N=30) not suitable for curative therapy and without approved treatment options
- IV administration once weekly
- Accelerated dose escalation in single patient cohorts followed by standard 3+3 design

Key Inclusion Criteria:

- Histologically confirmed advanced solid tumor with no approved therapeutic options
- Age 18 years or older
- ECOG performance status 0 or 1
- Measurable disease per RECIST v 1.1

IMMUNITY. RECRUITED.

Patients With Advanced Solid Tumors

Nearly Half Failed Prior Immunotherapy and/or Cold Tumors

Characteristics	
Total number of patients	N = 23 (cohorts 1 – 7)
Sex	10 (43%) ♀; 13 (57%) ♂
Age	Median 63 (Range 29-78)
Tumor types	
Colorectal	7 (30%)
Pancreas	5 (22%)
Head and Neck	3 (13%)
NSCLC	1 (4%)
Ovarian	2 (9%)
Rare tumor types	5 (22%)
Previous lines of therapy	Median 3 (Range 2-8)
PD1/PD-L1 experienced	11 (48%)

Well Tolerated Without DLTs, Hematological or Hepato-Toxicities

Summary

- DSP107 doses up to and including 10 mg/kg well tolerated
- No DLTs and no treatment-related SAEs
- No hematological toxicities
- No hepato-toxicities
- Very few AEs considered related to DSP107 and almost all mild or moderate in severity
- Most related AEs Grade 1-2 in severity. Only 2 related Grade 3 AEs – transient hypertension and fatigue (at EOT visit)

Now treating patients with DSP107 and Atezolizumab combination

Treatment-Related AEs in ≥ 2 Patients	
Total No of Patients	**N = 23 (cohorts 1 - 7)**
Treatment-related AEs (any grade)	**n (%)**
Any	16 (70)
IRR*	7 (30)
Diarrhea	4 (17)
Fatigue	4 (17)
Nausea	3 (13)
Constipation	2 (9)

*IRRs Grade 1-2 in severity. Easily abrogated (except 10-004 and 11-012 who withdrew consent) in subsequent infusions by reduced rate of infusion and concomitant IV fluids.

IMMUNITY. RECRUITED.

Receptor Occupancy Data Showed Immune Cell Target Engagement With No RBC Binding

Dose dependent target engagement achieved with 100% receptor occupancy on circulating immune cells observed from 3 mg/kg





DSP107 Does Not Bind Red Blood Cells

Resulting in Favorable Safety Profile With No Anemia or Antigen Sink Issues





Red Blood Cell



On RBCs CD47 protein complex is anchored to cytoskeleton resulting in its immobilization and low affinity of DSP107 to the monomeric CD47

High affinity/avidity of DSP107 to CD47 clusters on cancer cells

Tumor



IMMUNITY. RECRUITED.

DSP107 Treatment Resulted in Tumor Necrosis

Key paired biopsies data

- All biopsies collected from hepatic metastases pre-treatment and following cycle 2 (6 doses)
- H&E stained slides assessed by independent, blinded pathologist and by objectively by IF
- In 3 out of 6 paired biopsies significant increase in necrotic (dead) tumor tissue was observed – confirmed objectively by IF
- Necrosis associated with immune cell infiltration; no evidence of vascular necrosis

Patient Number	Dose (mg/kg)	Tumor type	Timepoint	% Necrosis (H&E)	% Necrosis (IF)
11-001	0.3	Colorectal	Screening	0	0
			6 weeks	**65**	**28**
11-002	0.3	Colorectal	Screening	2	2.1
			6 weeks	**35**	**22**
10-003	1	Pancreatic	Screening	10	10
			6 weeks	**50**	**26.6**
13-005	1	Pancreatic	Screening	4	4.9
			6 weeks	3	5.25
13-007	3	Neuroendocrine GI	Screening	0	0
			6 weeks	0	0
11-010	10	Appendiceal carcinoma	Screening	15	10.75
			6 weeks	**15**	**15.17**

IMMUNITY. RECRUITED.

Case Study: Increased Tumor Necrosis Associated With Immune Cell Infiltration



~ 65%

of the tumor tissue necrotic 6 weeks post DSP107 treatment (no necrosis at baseline)

Paired biopsy from colon carcinoma patient (11-001) in dose level 4 (0.3 mg/kg) pre- treatment and following cycle 2 (6 doses)

IMMUNITY. RECRUITED.

Case Study: Paired Biopsies Demonstrated Adaptive Immune Engagement in Ongoing Clinical Trial

6-wks post DSP107 treatment





Paired biopsy from colon carcinoma patient (11-001) in dose level 4 (0.3 mg/kg) pre- treatment and following cycle 2 (6 doses). Quantification of multiplex image analysis from biopsy stains.

Significant infiltration of T cells and NK cells in both the tumor compartment and at the tumor margin following DSP107 treatment

IMMUNITY. RECRUITED.

Best Overall Response After DSP107 Monotherapy

Indication	Dose	Patient #
NSCLC	1>3	10-004§
Colorectal	10	11-011
Colorectal	0.3	13-004
Anal	10	11-012§
Colorectal	10	11-009
Neuroendocrine GI	3	13-007
Ovarian	1	12-003
Colorectal	0.3	11-001^
Head & Neck	0.1	13-003
Pancreas	0.3	12-001
Appendiceal	10	11-010^
Colorectal	3	11-006
Eccrine Porocarcinoma	3	10-006
Pancreas	1	13-005
Pancreas	1	10-003^
Pancreas	1	12-002
Colorectal	0.3	11-002^
Head & Neck	0.03	13-002
Neuroendocrine Lung	0.01	13-001
Ovarian	10	12-005
Adrenal	3	13-006
Head & Neck	1	12-004
Pancreas	10	13-009



^Necrosis inductions evident in on-treatment biopsy; § Patient withdrawn

Summary

Best response from 22 evaluable patients:

SD = 11 (50%)

PD = 11 (50%) incl. 2 patients withdrawn before 1st CT scan due to clinical progression

IMMUNITY. RECRUITED.

DSP107 Phase I/II Data: Favorable Preliminary Safety and Activity in Advanced Solid Tumors

Clinical Overview

- DSP107 as monotherapy and in combination with Atezolizumab is being evaluated in a dose escalation trial
- 23 patients with diverse solid tumors have been treated with DSP107 monotherapy with 22 patients evaluable for efficacy analysis
- Now treating patients with DSP107 and Atezolizumab
- Phase Ib in r/r AML and MDS is ongoing assessing the safety of DSP107 monotherapy, DSP107 with Azacitidine and DSP107 with Azacitidine plus Venetoclax

Key Findings

- Low-grade AEs with no DLTs, no hematological toxicities and no hepato-toxicities
- Receptor occupancy data suggesting lack of RBC binding and immune cell engagement
- Increased immune cell infiltration into the tumor and tumor necrosis
- 50% DCR in difficult to treat phase I patients

Next steps: Further evaluate safety and efficacy of DSP107 monotherapy and combination with SOC therapies

IMMUNITY. RECRUITED.

DSP107 Highlights

MOA

- CD47 inhibition (Cancer specific)
- 4-1BB activation (CD47-conditional)

Differentiation

- Activates both adaptive and innate immunity
- No RBC binding observed
- Potentially favorable safety profile suitable for combination therapy

Clinical Opportunities

- Solid tumors
  - DSP107 ± atezolizumab (intended to enhance T cell activation)
- Hematological Malignancies
  - DSP107 ± azacytidine + venetoclax (intended to enhance eat me signal)

Potential Efficacy - Preclinical

- Activates T cells, increases IFNγ secretion and anti-tumor killing
- Increased macrophage phagocytosis of tumor cells
- Augments mAbs' ADCP phagocytosis of cancer cells
- Potential efficacy as monotherapy and synergistic activity in combination

Potential Safety - Preclinical

- No binding to human RBCs observed
- No CD47 related hematological toxicities observed
- No 4-1BB related hepato-toxicities observed

Preliminary Clinical Data

Well tolerated

- No DLTs
- No hematological toxicities
- No hepato-toxicities

Preliminary efficacy signals as a monotherapy in solid tumors

- Paired biopsies demonstrate tumor necrosis
- Stable disease achieved in eleven of twenty-two patients (50%)

IMMUNITY. RECRUITED.

DSP502

MIRP Type	**DSP-Fc**
Targets	**PVR, PD-L1, FcR**
Primary Cell Target	**NK cells, T effector cells**
Mechanism of Action	**Dual checkpoint inhibition designed to unleash NK and T-cells, ADCC**

Dual Checkpoint Binding Aimed at Enhancing Selectivity and Synergistic Immunity

1. Dual binding to overexpressed checkpoints may enable high tumor specificity
2. Potential anti-tumor immunity via simultaneous checkpoint inhibition of PVR and PD-L1
3. Active Fc may extend half-life and enhance ADCC activity



IMMUNITY. RECRUITED.

Novel, Potential Next-Generation Approach to Checkpoint Inhibition

- PVR is a ligand for inhibitory (TIGIT, CD96) and stimulatory (DNAM1) immune checkpoint receptors
- Tumor cells overexpress PVR to evade immune surveillance
- Overexpression of PVR is associated with resistance to checkpoint therapy in NSCLC and melanoma patients
- Inhibition of TIGIT/PVR is efficacious in combination with PD1 blockade
- PD1 inactivates DNAM1 stimulatory activity



Immunosuppression is the net effect of PVR and PD1 overexpression in the TME

Synergistic Dual Checkpoint Inhibition for Robust Anti-tumor Immunity

1. Simultaneous TIGIT, CD96 and PD-L1 inhibition with DNAM1 costimulation for enhanced anti-tumor immunity
2. Designed to activate both, T cells and NK cells

Effect	Dual PVR and PD-L1 Targeting (KAHR's approach)	TIGIT Ab* (Competitors)
− TIGIT	✓	✓
− CD96	✓	—
+ DNAM1	✓	—
− PD-1	✓	—

*Company has not undertaken comparative trials of DSP502 against the identified competitors



DSP502 blocks PVR and PD1 signaling for enhanced immune activation and anti-tumor immunity



DSP502 – Differentiated TIGIT/PD1 Targeting Compound

Potential next-generation capabilities

Dual MOA
designed to activate innate and adaptive immunity

High Tumor Specificity
Concomitant binding to PVR and PD-L1 required for its activity

Designed to Have Unique Features
Multiple functionalities that act simultaneously for synergistic effect

Differentiated mechanism of action



Enhanced NK cells cancer killing potential



Augmented NK cells ADCC activity



Demonstrated potent single agent anti tumor activity

DSP216

MIRP Type	**DSP-Fc**
Targets	**CD47, HLA-G**
Primary Cell Target	**mϕ macrophages, T effector cells, NK cells, Myeloid cells**
Mechanism of Action	**Dual checkpoint inhibition unleash macrophage, NK and Teff**

Dual Checkpoint Binding Designed For Enhanced Selectivity and Broad Immunity

1. Dual binding to overexpressed cancer checkpoints may enable high tumor specificity
2. HLA-G and CD47 blockade designed to activate innate and adaptive immunity
3. Inactive Fc may extend half-life



HLA-G Blockade Designed To Prevent Immunotolerance Across Immune Cells

- Placenta expressed HLA-G triggers immunotolerance to prevent the mother's immune system from attacking the fetus
- Tumor cells overexpress HLA-G to evade immune surveillance
- HLA-G is a broad-range immune checkpoint that is the main ligand for the LILRB/ILT receptor family
- HLA-G inhibits multiple immune cell subsets and recruits suppressive immune cells to the tumor microenvironment



Dual Targeting Designed For Robust Tumor Selective Innate & Adaptive Immune Activation

1. HLA-G blockade aims to prevent cancer immunotolerance by **multiple immune cell subsets**

2. CD47 blockade removes ‘don’t eat me’ signal, triggering macrophage phagocytosis of tumor cells

Effect	HLA-G & CD47 (KAHR’s approach)	LILRB1/2 Ab* (Competitors)
− LILRB1 & LILRB2	✓	—
+ Tumor selectivity	✓	—
+ Innate & adaptive immunity	✓	—

*Company have not undertaken comparative trials of DSP502 against the identified competitors



DSP216 – First-in-Class HLA-G/CD47 Targeting Compound

Potential next-generation capabilities

Dual MOA
Designed to activate innate and adaptive immunity

High Tumor Specificity
Concomitant binding to HLA-G and CD47 required for its activity

Designed to Have Unique Features
Prevents cancer immunotolerance by multiple immune pathways

Differentiated mechanism of action



Enhanced phagocytosis cancer-killing



No binding to Red Blood Cells



Polarizes M2 Into M1 Anti-Tumor Macrophages

CORPORATE HIGHLIGHTS

Multifunctional Cancer Immunotherapy Candidates Targeting Innate and Adaptive Immune Cells

NOVEL MIRPs™
Multifunctional Immuno-Recruitment Proteins – versatile platform targeting both innate & adaptive immunity across cancers

DIFFERENTIATED PIPELINE
- Novel, next-generation potential across three programs
- Lead candidate DSP107 –
  CD47 inhibition (Cancer specific)
  41BB activation (CD47-conditional)

ANTICIPATED MILESTONES
-DSP107| Interim Ph II solid tumor mono and combo data Q2 2023 and interim Ph I hematological malignancy data Q4 2022
-DSP502 & DSP216 | IND 2024

MARKET
Immuno-therapeutics
$50.2B by 2026

IP
13 families
4 granted (US and other territories),
73 pending (NP worldwide and PCT stage)

Experienced Leadership
Management team, BOD and SAB comprised of leading experts including technology inventor, Prof. Mark Tykocinski, Dean of the School of Medicine and Provost, Thomas Jefferson University.

IMMUNITY. RECRUITED.

Recent Achievements and Milestones

Achievements To Date	Date
Financing	
$5 million – Cancer Focus Fund to finance DSP107 clinical trial in blood cancers	May 2021 ✓
$56.6 million – Round E financing	June 21-22 ✓
Clinical	
Completion of DSP107 monotherapy dose escalation in DSP107_001 solid tumor phase I study	Dec 2021 ✓
Completion of first DSP107+Tecentriq cohort under clinical trial collaboration with Roche	Jan 2022 ✓
Initiation of DSP107_002 AML/MDS phase Ib study	Feb 2022 ✓
Corporate	
Composition of matter patent granted in EU and US for DSP107	H2 2021 ✓
DSP107 paper published in a high impact peer-reviewed journal	Mar 2022 ✓

Scientific Advisors and Board of Directors

Scientific and Clinical Advisory Board

Mark L. Tykocinski, MD
KAHR technology inventor; BOD Observer; Provost Jefferson Thomas University

Martin S. Tallman, MD
Chief Leukemia Service, Memorial Sloan Kettering Cancer Center

Ezra Cohen, M.D.
Director San Diego Center for Precision Immunotherapy

Hagop Kantarjian, M.D.
Chair Department of Leukemia at The University of Texas MD Anderson Cancer Center

Edwin Bremer, PhD
Professor at the Translational Surgical Oncology at the University Medical Center Groningen

Samir Khleif, MD
Director, Loop Immuno-Oncology Research Lab, Georgetown Lombardi Comprehensive Cancer Center

Manuel Hidalgo, M.D., Ph.D
Chief Division of Hematology and Medical Oncology, Weill Cornell

Board of Directors

Aron Knickerbocker
President & CEO of Aulos Bioscience, co-founder of RayzeBio; 25+ years as a leader in biotech

Thomas Eldered
Chairman and owner of Flerie Invest AB; 25+ yrs in biotech and life sciences

Gur Roshwalb
Managing Director at aMoon; 20+ yrs in healthcare and finance

Merav Kaye
Investment manager in Consensus Business Group; 7+ yrs project management and business development

Carl-Johan Spak
Senior Advisor at Flerie Invest; 30+ yrs in pharmaceutical industry

Tamar Raz
CEO of Hadasit and chairperson of HBL; 20+ yrs in biotech and life sciences

Eyal Lifschitz
General Partner and Co-Founder of Peregrine Ventures; 20+ yrs managing biotech companies

Michel Habib
Co-Founder & Managing General Partner at ALIVE Israel HealthTech Fund; 20+ yrs investing in biotech